Semaglutide Medication: FDA Uses, Mechanism, Side Effects

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Part of the PlexusDx Education Hub, this article explains semaglutide as a medication and the genetics that surround it.

Semaglutide is among the most-searched drug names in the GLP-1 landscape as of April 2026, and readers often just want a straight explainer. This page treats it as a medication first: what it is, how it works, what the evidence base looks like, which side effects show up most, and the genetic variables that sit upstream of any compound decision.

What the medication is

Semaglutide is a GLP-1 pathway compound in the receptor agonist class, marketed under separate brand names for separate approved uses. Understanding it as a class member first helps explain why its mechanics, cautions, and evidence overlap with related compounds even when the labeling differs by product and indication.

How it works mechanically

GLP-1 receptor agonists and GIP/GLP-1 dual agonists act on appetite regulation, satiety signaling, and gastric emptying, reducing caloric intake through mechanism-driven change rather than willpower. Body-weight and glucose effects depend on the specific compound, dose, adherence, and individual factors. Approved dosing is titrated upward from a starting dose over several weeks per each product's label.

The evidence base

Different trial programs answer different questions: SURMOUNT and SURPASS for tirzepatide, STEP and SUSTAIN for semaglutide, AWARD for dulaglutide, and LEAD and LEADER for liraglutide. Effect sizes on body weight, A1C, and cardiovascular endpoints vary by population, dose, and endpoint. Primary sources include The New England Journal of Medicine, The Lancet, and The Lancet Diabetes and Endocrinology.

Side effects and cautions

GLP-1 receptor agonists and GIP/GLP-1 dual agonists carry the class boxed warning for thyroid C-cell tumor risk observed in rodent studies, and are contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Common side effects are gastrointestinal, meaning nausea, vomiting, diarrhea, and constipation, and peak during escalation. Rare serious events include pancreatitis, gallbladder disease, and dehydration-related acute kidney injury.

Why individual results differ

Even with identical labeling, people respond differently, and part of that variation is inherited. Appetite set-point, glucose handling, and satiety signaling reflect biology present before the first dose. Recognizing that layer helps frame realistic expectations and better questions for a clinical visit.

The genes that map metabolism

Variants in FTO, MC4R, and TCF7L2 shape baseline GLP-1 activity, appetite regulation, and energy balance. The Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights across these markers. It does not predict response to a medication and is not pharmacogenomic; it pairs with the Weight Management Protocols as upstream context for a provider conversation.

Questions worth bringing to a prescriber

Because this is a medication first, the most useful thing a reader can do is arrive at a visit with focused questions rather than conclusions. Which indication applies to your situation, how tolerability will be monitored, what symptoms should prompt an earlier call, and how progress will be assessed are all reasonable things to raise. So is an honest discussion of medical history, concurrent medications, and the contraindications listed in the label. A clinician can only individualize care with accurate information, and a prepared patient makes that easier. None of this replaces professional judgment, but it does turn a passive appointment into a genuine exchange. Understanding your metabolic baseline beforehand can make those questions sharper, which is where the genetic context below fits, offering upstream self-knowledge rather than an answer the test is not designed to give.

Approached as a medication rather than a headline, semaglutide becomes far easier to reason about: a defined mechanism, a mapped evidence base, a known side-effect profile, and an inherited backdrop that explains individual variation. That clarity is exactly what a productive prescriber conversation is built on.

Frequently Asked Questions

How does semaglutide work as a medication?

Semaglutide acts on the GLP-1 pathway, raising satiety signaling, slowing gastric emptying, and reducing appetite. Its effect depends on the compound, dose, adherence, and individual factors, and approved dosing is titrated upward per the product label. Discuss the mechanism and whether it fits your situation with a qualified healthcare provider.

What are the most common side effects?

Gastrointestinal symptoms lead the list, including nausea, vomiting, diarrhea, and constipation, and they usually peak during dose escalation. The class carries a boxed warning for thyroid C-cell tumor risk seen in rodents, and rare serious events include pancreatitis and gallbladder disease. Report concerning symptoms to your provider promptly.

Which trials describe semaglutide?

Semaglutide is studied in the STEP and SUSTAIN programs, with related compounds covered by SURMOUNT, SURPASS, AWARD, LEAD, and LEADER. Effect sizes vary by population, dose, and endpoint, and are published in journals including The New England Journal of Medicine and The Lancet. Discuss the outcomes relevant to you with a provider.

Does genetics change how the medication works for me?

Inherited variants in FTO and MC4R, and TCF7L2 shape appetite and glucose biology, which is one reason responses differ. The Precision Peptide Genetic Test reviews these at the pathway level. It does not predict drug response or set a dose; it provides upstream context to discuss with your healthcare provider.

Continue with more explainers in the PlexusDx Education Hub.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.